Chintan H Kapadia
Overview
Explore the profile of Chintan H Kapadia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kapadia C, Luo B, Dang M, Irvin-Choy N, Valcourt D, Day E
J Appl Polym Sci
. 2021 Jan;
137(25).
PMID: 33384460
Abnormal expression of microRNAs (miRNAs), which are highlyconserved noncoding RNAs that regulate the expression of various genes post transcriptionally to control cellular functions, has been associated with the development of...
2.
Perry J, Tian S, Sengottuvel N, Harrison E, Gorentla B, Kapadia C, et al.
ACS Nano
. 2020 May;
14(6):7200-7215.
PMID: 32463690
CpG oligodeoxynucleotides are potent toll-like receptor (TLR) 9 agonists and have shown promise as anticancer agents in preclinical studies and clinical trials. Binding of CpG to TLR9 initiates a cascade...
3.
Valcourt D, Kapadia C, Scully M, Dang M, Day E
Adv Healthc Mater
. 2020 May;
9(12):e2000110.
PMID: 32367687
Significant advances have been made in the development of nanoparticles for cancer treatment in recent years. Despite promising results in preclinical animal models, cancer nanomedicines often fail in clinical trials....
4.
Kapadia C, Ioele S, Day E
J Biomed Mater Res A
. 2019 Nov;
108(3):601-613.
PMID: 31742868
Triple-negative breast cancer (TNBC) accounts for 15-25% of diagnosed breast cancers, and its lack of a clinically defined therapeutic target has caused patients to suffer from earlier relapse and higher...
5.
Kapadia C, Tian S, Perry J, Luft J, DeSimone J
ACS Omega
. 2019 Apr;
4(3):5547-5555.
PMID: 30972374
Multiple studies have been published emphasizing the significant role of nanoparticle (NP) carriers in antigenic peptide-based subunit vaccines for the induction of potent humoral and cellular responses. Various design parameters...
6.
Goyal R, Kapadia C, Melamed J, Riley R, Day E
Cell Mol Bioeng
. 2018 Dec;
11(5):383-396.
PMID: 30555597
Introduction: MicroRNAs (miRNAs) are short noncoding RNAs whose ability to regulate the expression of multiple genes makes them potentially exciting tools to treat disease. Unfortunately, miRNAs cannot passively enter cells...
7.
Kapadia C, Melamed J, Day E
BioDrugs
. 2018 Jul;
32(4):297-309.
PMID: 29959665
Spherical nucleic acids (SNAs) are highly oriented, well organized, polyvalent structures of nucleic acids conjugated to hollow or solid core nanoparticles. Because they can transfect many tissue and cell types...
8.
Kapadia C, Tian S, Perry J, Sailer D, Luft J, DeSimone J
J Control Release
. 2017 Nov;
269:393-404.
PMID: 29146244
Tumor-specific CD8 cytotoxic T lymphocytes (CTLs) play a critical role in an anti-tumor immune response. However, vaccination intended to elicit a potent CD8 T cell responses employing tumor-associated peptide antigens,...
9.
Kapadia C, Tian S, Perry J, Luft J, DeSimone J
Mol Pharm
. 2016 Aug;
13(10):3381-3394.
PMID: 27551741
Educating our immune system via vaccination is an attractive approach to combat infectious diseases. Eliciting antigen specific cytotoxic T cells (CTLs), CD8 effector T cells, is essential in controlling intracellular...
10.
Kapadia C, Perry J, Tian S, Luft J, DeSimone J
J Control Release
. 2015 Oct;
219:167-180.
PMID: 26432555
Although surgery, radiation therapy, and chemotherapy have significantly improved as treatments for cancer, they can rarely control metastatic disease and cures remain scarce. Promising recent developments suggest that cancer immunotherapy...